Pneumococcal Infections¶
Chapter 151 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Pneumococcal infections are caused by Streptococcus pneumoniae, with the polysaccharide capsule as a key virulence factor.
- Serotype distribution varies by age, geography, and disease syndrome, with serotypes 19A, 6B, and 14 being prominent in invasive disease.
- Antibiotic resistance, particularly to β -lactams, is widespread, driven by genetic mutations and horizontal gene transfer.
- Vaccination with PCVs (polysaccharide-protein conjugate vaccines) has reduced vaccine-serotype disease but led to serotype replacement.
- Clinical management requires tailored antibiotic regimens based on resistance patterns and patient age.
1. DEFINITION & OVERVIEW¶
Pneumococcal infections are caused by Streptococcus pneumoniae, a gram-positive bacterium. The capsule, composed of polysaccharides, is critical for virulence by resisting phagocytosis. The organism is divided into 99 serotypes based on capsule structure, with serotypes 1, 5, 6B, 14, 19F, and 23F historically causing most invasive disease.
Table 151-1: Clinical Risk Groups for Pneumococcal Infection¶
| CLINICAL RISK GROUP | EXAMPLES |
|---|---|
| Asplenia or splenic dysfunction | Sickle cell disease, celiac disease |
| Chronic respiratory disease | COPD, bronchiectasis, cystic fibrosis |
| Chronic heart disease | Ischemic heart disease, congenital heart disease |
| Chronic kidney disease | Nephrotic syndrome, renal transplantation |
| Diabetes mellitus | Type 1 or type 2 diabetes requiring insulin |
| Immunocompromise | HIV, primary immunodeficiency, leukemia |
| Cochlear implants | |
| Cerebrospinal fluid leaks | |
| Miscellaneous | Infancy, old age, prior hospitalization, alcoholism, smoking |
1.1 Microbiology¶
S. pneumoniae is a gram-positive diplococcus with α -hemolytic activity. Capsule types (serotypes) determine pathogenicity, with 99 recognized serotypes. The capsule prevents complement-mediated phagocytosis and is a target for protective antibodies.
1.2 Virulence Factors¶
Key virulence factors include pneumolysin (cytotoxin), pneumococcal surface protein A (PspA), and the capsule. These factors mediate immune evasion, adhesion, and tissue invasion.
2. EPIDEMIOLOGY¶
Pneumococcal infections are a leading cause of morbidity and mortality globally, particularly in children <5 years and adults ≥ 65 years. Serotype distribution varies by region and age, with vaccine-serotype replacement observed post-PCV introduction.
2.1 Incidence & Prevalence¶
Pneumococcal disease is more common in colder months and among males. In the U.S., Native American and African American populations have higher rates due to socioeconomic factors and comorbidities.
2.2 Risk Factors¶
Risk factors include splenic dysfunction, immunocompromise, chronic diseases (COPD, diabetes), and prior antibiotic use. Nasopharyngeal colonization is common, with ~50% of children colonized by 1 year of age.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
S. pneumoniae colonizes the nasopharynx, with transmission via respiratory droplets. The capsule mediates immune evasion, while adhesins like PsaA and PspA facilitate colonization. Biofilm formation and antibiotic resistance mechanisms contribute to persistence.
3.1 Capsule & Immune Evasion¶
The polysaccharide capsule prevents phagocytosis by blocking complement deposition. Capsular types are serotype-specific, with cross-protection limited to certain serotypes (e.g., 6B vs. 6A).
3.2 Antimicrobial Resistance¶
Resistance to β -lactams (penicillin, cephalosporins) is driven by mutations in penicillin-binding proteins (PBPs) and horizontal gene transfer. Multidrug resistance is now global, with high rates in some regions.
4. CLINICAL FEATURES¶
Clinical manifestations vary by infection site: pneumonia (cough, fever, hypoxia), meningitis (stiff neck, altered mental status), and otitis media (ear pain, fever). Nonbacteremic pneumonia is common but difficult to diagnose.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include viral pneumonia, other bacterial pathogens (e.g., H. influenzae, Legionella), and non-infectious causes (e.g., heart failure, pulmonary embolism). Abdominal symptoms may mimic cholecystitis or appendicitis.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis relies on clinical suspicion, imaging (chest X-ray for pneumonia), and laboratory tests (blood cultures, CSF analysis, urinary antigen tests). PCR and serotyping aid in identifying causative serotypes.
6.1 Diagnostic Tests¶
Urinary antigen tests (detecting C-polysaccharide) are highly specific in adults but less so in children. CSF analysis for turbidity, elevated protein, and low glucose confirms meningitis.
7. MANAGEMENT & TREATMENT¶
Antibiotic therapy is guided by resistance patterns and patient age. First-line agents include β -lactams (ampicillin, cefotaxime) for susceptible strains. Vancomycin is reserved for resistant isolates. Supportive care (e.g., corticosteroids) is critical in severe cases.
7.1 Antibiotic Regimens¶
For adults: vancomycin (30–60 mg/kg/day) + cefotaxime/ceftriaxone. For children: amoxicillin (80–90 mg/kg/day) or high-dose amoxicillin-clavulanate. Macrolides are alternatives for penicillin-allergic patients.
7.2 Supportive Care¶
Corticosteroids reduce mortality and sequelae in adults with meningitis. Mechanical ventilation and ICU care are required for severe pneumonia or sepsis.
8. PROGNOSIS & COMPLICATIONS¶
Mortality for pneumococcal meningitis is ~20%, with 50% of survivors experiencing long-term complications (e.g., hearing loss, hydrocephalus). Complications include empyema, septic arthritis, and meningococcal sepsis.
9. SPECIAL CONSIDERATIONS¶
Vaccination is recommended for high-risk groups (elderly, immunocompromised, children). PCVs reduce vaccine-serotype disease but may drive non-vaccine serotype emergence. In pregnancy, antibiotics are chosen to avoid fetal risk.
10. KEY POINTS & CLINICAL PEARLS¶
- The capsule is central to pathogenesis and vaccine development. 2. PCV use has reduced vaccine-serotype disease but led to serotype replacement. 3. Antibiotic resistance is widespread; vancomycin is reserved for resistant isolates. 4. Corticosteroids improve outcomes in adult meningitis. 5. Early diagnosis and targeted therapy are critical to prevent complications.